• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

    2/6/25 8:30:00 PM ET
    $COR
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $COR alert in real time by email

    Transaction Highlights

    • Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares
    • Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares
    • Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional cash proceeds at maturity. These remaining prepaid variable share forward contracts are mainly scheduled to mature during March, June and September of calendar year 2025.
    • Use of proceeds will primarily be for debt paydown, as the Company proactively seeks to address its debt maturities in fiscal year 2026, and for general corporate purposes

    Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into with various financial institutions, with respect to shares of Cencora, Inc. (NYSE:COR). Under these transactions, the Company had previously received cash payments in an aggregate amount of approximately $1.1 billion on or about the dates of first entering into them. The transactions were scheduled to mature during March and June of calendar year 2026.

    As part of the early settlement of the transactions prior to their scheduled maturities, WBA will deliver to the financial institutions an aggregate of approximately 6.1 million shares of Cencora, while paying a net aggregate cash payment of approximately $20 million. The transaction fulfills the Company's obligations to deliver shares at a future date to each financial institution participating in the early settlement. These contracts have accreted cash value to the Company as a result of participation in the appreciation of Cencora's stock since entering the transactions in 2023. The early settlement together with the concurrent share sale realizes the embedded cash value that exists in the prepaid variable share forwards.

    Concurrent with these early settlements, WBA today announced that it has sold shares of Cencora common stock in an unregistered block trade pursuant to Rule 144 for proceeds of approximately $265 million, and has sold additional shares in a share repurchase by Cencora for additional proceeds of approximately $50 million.

    Proceeds to WBA will be used primarily for debt paydown and general corporate purposes. The proceeds from these transactions as well as other actions, including the recent suspension of the dividend, further help position the Company to address its upcoming debt maturities in fiscal 2026.

    Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 10 percent to approximately six percent.

    The sale has no impact to the long-term partnership between the two companies. Walgreens Boots Alliance remains fully committed to the strategic, mutually beneficial relationship with Cencora, which has been a strong and trusted partner since 2013. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on Cencora's Board of Directors.

    About Walgreens Boots Alliance

    Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.

    A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.

    WBA employs approximately 311,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.

    More Company information is available at www.walgreensbootsalliance.com.

    (WBA-GEN)

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250206482504/en/

    WBA Media Relations

    USA / Jim Cohn, [email protected]

    WBA Investor Relations

    Eric Wasserstrom, [email protected]

    Get the next $COR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR
    $WBA

    CompanyDatePrice TargetRatingAnalyst
    Cencora Inc.
    $COR
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    Walgreens Boots Alliance Inc.
    $WBA
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    Cencora Inc.
    $COR
    12/4/2024$280.00Outperform
    Mizuho
    Cencora Inc.
    $COR
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    Walgreens Boots Alliance Inc.
    $WBA
    2/26/2024$23.00Market Perform
    Leerink Partners
    Cencora Inc.
    $COR
    2/26/2024$261.00Outperform
    Leerink Partners
    Walgreens Boots Alliance Inc.
    $WBA
    2/20/2024Hold → Reduce
    HSBC Securities
    Walgreens Boots Alliance Inc.
    $WBA
    1/3/2024$21.00Underweight
    Barclays
    More analyst ratings

    $COR
    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Walgreens Specialty Pharmacy Strengthens Market Position Through Expanded Limited Distribution Network

    Walgreens Specialty Pharmacy network grows manufacturer relationships in limited distribution drug space Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to now include 265 products, placing it among the leading networks in specialty pharmacies. LDDs are specialty medications that are available through select specialty pharmacies chosen by the drug manufacturer and are often medications with complex regimens, high costs and/or require special handling. As the largest independent specialty pharmacy not directly affiliated with a pharmacy benefit manager (PBM), Walgreens Specialty Pharmacy is able to collaborate with any partner. "As the limited distri

    8/19/25 9:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Blazing Star Merger Sub, Inc. announces extension of the expiration time and settlement date for the previously announced Tender Offer and Consent Solicitation for any and all Walgreens Boots Alliance, Inc.'s 3.600% senior notes due 2025, 2.125% senior notes due 2026, 3.450% notes due 2026, 8.125% notes due 2029, 3.200% Notes due 2030, 4.500% senior notes due 2034, 4.800% senior notes due 2044, 4.650% notes due 2046 and 4.100% Notes due 2050, and any and all of Walgreen Co.'s 4.400% notes due 2042

    NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the extension of the Expiration Time and the Settlement Date (as defined below) for (A) the previously announced cash tender offers (each, an "Offer" and, collectively, the "Tender Offer") for any and all of Walgreens Boots Alliance, Inc.'s (NASDAQ:WBA) ("WBA") outstanding (1) 3.600% senior notes due 2025 (the "2025 Notes"), (2) 2.125% senior notes due 2026 (the "2.125% 2026 Notes"), (3) 3.450% notes due 2026 (the "3.450% 2026 Notes"), (4) 8.125% notes due 2029 (the "2029 Notes"), (5) 3.200% notes due 2030 (the "2030 Notes"), (6) 4.500% senior notes due 2034 (the "2034 Notes"), (7) 4.800% sen

    8/18/25 7:04:00 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Cencora Reports Fiscal 2025 Third Quarter Results

    Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

    8/6/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cencora upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

    6/3/25 7:24:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

    2/28/25 7:36:45 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Mizuho resumed coverage on Cencora with a new price target

    Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

    12/4/24 7:30:44 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/15/24 5:45:26 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $COR
    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $COR
    $WBA
    SEC Filings

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 10-Q filed by Cencora Inc.

    10-Q - Cencora, Inc. (0001140859) (Filer)

    8/6/25 2:27:19 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    8/6/25 6:34:52 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cencora Inc.

    SCHEDULE 13G/A - Cencora, Inc. (0001140859) (Subject)

    7/29/25 11:23:15 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $COR
    $WBA
    Financials

    Live finance-specific insights

    View All

    Cencora Reports Fiscal 2025 Third Quarter Results

    Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

    8/6/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

    Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

    7/11/25 9:59:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

    7/3/25 7:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

    Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

    10/7/24 8:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

    Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

    8/16/24 9:00:00 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $COR
    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:18:27 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Director Graham Ginger L

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:15:35 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 4 filed by Director Babiak Janice M.

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    8/15/25 6:13:29 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples